Navigating the HER2 Treatment Paradigm for Breast Cancer

Navigating the HER2 Treatment Paradigm for Breast Cancer

Navigating the HER2 Treatment Paradigm for Breast Cancer

Learn how you can implement appropriate treatment strategies for your patients with HER2+ breast cancer. 

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment strategies for patients with HER2+ breast cancer.

  • Target Audience

    This activity has been designed to meet the educational needs of oncologists and other healthcare professionals managing patients with breast cancer.

  • Learning Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Distinguish between approved HER2-directed therapies to optimize sequencing throughout the treatment continuum.
    • Discuss potential additional indications for recently approved agents used in the treatment of metastatic HER2+ breast cancer, based on currently available data and ongoing clinical trials.
    • Identify the adverse effects seen with recently approved anti-HER2 therapies and recommend appropriate monitoring and management strategies to optimize therapy.
  • Commercial Support

    This activity is supported by independent educational grants from Daiichi Sankyo and AstraZeneca.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Medical Education Resources and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Novus Medical Education. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    MER designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    MER requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    MER has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Dr. Modi discloses the following relationships:
    Advisor/Consultant: Seagen, Daiichi-Sankyo, AstraZeneca, Genentech/Roche, Macrogenics, Zymeworks, Novartis, GlaxoSmithKline
    Research Support: Seagen, Daiichi-Sankyo, AstraZeneca, Genentech/Roche

    Dr. Hurvitz discloses the following relationships:
    Research Support: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Cytomx, Daiichi-Sankyo, Dignitana, Genentech/Roche, Roche, Gilead, GlaxoSmithKline, Immunomedics, Eli Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Orinove, Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, Zymeworks, Phoenix Molecular Designs, Ltd.
    Advisor/Consultant: Novartis, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Genentech/Roche, Sanofi

    The directors, planners, managers, and reviewers of this activity reported no relevant financial relationships with an ineligible company during the past 24 months.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact MER at or 800.421.3756.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free